Laninamivir Octanoate Hydrate Drug Due Diligence Report 2026

This Laninamivir Octanoate Hydrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Laninamivir Octanoate Hydrate can convert its Small molecule drug profile and Influenza A neuraminidase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Laninamivir Octanoate Hydrate (query alias: Laninamivir Octanoate Hydrate)
Modality / target	Small molecule drug; Influenza A neuraminidase; neuraminidase inhibitors
Highest global status	Approved
Originator	Daiichi Sankyo Co., Ltd.
Active developers	Daiichi Sankyo Co., Ltd.

The MCP disease footprint includes Influenza A virus infection, Influenza B virus infection. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2080223342	Phase 3	completed	500	safety efficacy confirmatory Time to alleviation of influenza illness
JPRN-jRCT2080223343	Phase 3	completed	150	safety efficacy confirmatory Time to alleviation of influenza illness
NCT05648448	Phase 2	Recruiting	3000	Rate of viral clearance for currently available drugs and those with potential activity

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B

Phase 1/2; n=15; evaluation: not stated. Reported fields: To Evaluate Time to First Alleviation of a Composite of Influenza Symptoms and Absence of Fever.(Mean) = 85.1 hours (Standard Deviation, 34.2); -; -

A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection

Phase 2; n=639; evaluation: not stated. Reported fields: Time to Alleviation of Influenza Symptoms(Median) = 104.10 hours (95% Confidence Interval, 93.00 - 140.70); Time to Alleviation of Influenza Symptoms(Median): P-Value = 0.251; P-Value = 0.818; Time to Alleviation of Influenza Symptoms(Median) = 103.20 hours (95% Confidence Interval, 89.00 - 138.30)

A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection

Phase 3; n=1002; evaluation: not stated. Reported fields: Time to Alleviation of Influenza Illness(Median) = 73.6 hours (95% Confidence Interval, 68.5 - 83.3); Time to Alleviation of Influenza Illness(Median): Median Difference (Final Values) = -0.6(95% CI, -9.9 to 6.9), P-Value = 0.748; Median Difference (Final Values) = -12.8(95% CI, -18.2 to -0.4), P-Value = 0.038; Median Difference (Final Values) = 12.2(95% CI, -1.5 to 17.2), P-Value = 0.104; Time to Alleviation of Influenza Illness(Median): Median Difference (Final Values) = -0.6(95% CI, -9.9 to 6.9), P-Value = 0.748; Median Difference (Final Values) = -12.8(95% CI, -18.2 to -0.4), P-Value = 0.038; Median Difference (Final Values) = 12.2(95% CI, -1.5 to 17.2), P-Value = 0.104

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Laninamivir Octanoate Hydrate addresses Influenza A virus infection, Influenza B virus infection. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Influenza A neuraminidase records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-11-14	Merck pays $9.2B for Cidara, picking up flu antiviral spurned by J&J	Phase 3	US$9,200.0M stated total
2024-04-24	Cidara therapeutics reacquires global development and commercial rights to CD388 and announces private placement financing of $240 million	Preclinical	US$27.0M upfront; US$753.0M milestones; US$780.0M stated total
2020-05-19	黑龙江珍宝岛药业股份有限公司与广州市恒诺康医药科技有限公司签署技术转让及新药研发合同	Phase 1	US$7.9M upfront; US$15.8M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO